Sun Pharma launches LEQSELVI in US for treatment of severe alopecia areata
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Subscribe To Our Newsletter & Stay Updated